priors.science/reviews/giant-cell-arteritis

Giant Cell Arteritis

The current evidence on 8 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

8claims tracked
66primary papers reviewed
5 Jun 2026latest evidence review
Weeklyre-scored against new papers
2 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableGlucocorticoid monotherapy relapses on taperGlucocorticoidEstablished88%10
StableTocilizumab sustains glucocorticoid-free remissionTocilizumabEstablished87%10
StableTemporal artery halo sign diagnosticImagingLikely80%11
StableLarge-vessel ultrasound adds sensitivityImagingLikely80%9
StableRelapse common after tocilizumab discontinuationTocilizumabLikely79%9
StableUpadacitinib induces remissionEmergingLikely72%9
StableGlucocorticoids reduce vision lossGlucocorticoidLikely72%10
StableSecukinumab maintains remissionEmergingUncertain55%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic